GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petros Pharmaceuticals Inc (NAS:PTPI) » Definitions » Operating Margin %

Petros Pharmaceuticals (Petros Pharmaceuticals) Operating Margin % : 1,384.34% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Petros Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Petros Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-5.04 Mil. Petros Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $-0.36 Mil. Therefore, Petros Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 was 1,384.34%.

The historical rank and industry rank for Petros Pharmaceuticals's Operating Margin % or its related term are showing as below:

PTPI' s Operating Margin % Range Over the Past 10 Years
Min: -264.45   Med: -184.85   Max: -108.29
Current: -184.84


PTPI's Operating Margin % is ranked worse than
89.71% of 1020 companies
in the Drug Manufacturers industry
Industry Median: 6.075 vs PTPI: -184.84

Petros Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Petros Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-5.04 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.76 Mil.


Petros Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Petros Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Petros Pharmaceuticals Operating Margin % Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
-108.29 -180.79 -231.06 -264.45 -184.85

Petros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -513.91 -51.99 -123.52 -116.54 1,384.34

Competitive Comparison of Petros Pharmaceuticals's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Petros Pharmaceuticals's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's Operating Margin % falls into.



Petros Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Petros Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-10.762 / 5.822
=-184.85 %

Petros Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-5.039 / -0.364
=1,384.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Petros Pharmaceuticals  (NAS:PTPI) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Petros Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Petros Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Greg Bradley director 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
John D Shulman director, 10 percent owner
Jcp Iii Sm Aiv, L.p. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, L.p. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, Ltd. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Metp Holdings Llc 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Keith Lavan officer: Chief Financial Officer 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Fady Boctor officer: Pres. & Chief Comm. Officer 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Andrew Gesek officer: President, Timm Medical 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Metuchen Therapeutics, Llc 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Mitchell Arnold officer: Prin. Acct. Off/Prin. Fin. Off 200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726

Petros Pharmaceuticals (Petros Pharmaceuticals) Headlines